Cargando…

Cohort profile: the Swedish Prescribed Drugs and Health Cohort (SPREDH)

PURPOSE: The Swedish Prescribed Drugs and Health Cohort (SPREDH) is a Swedish population-based cohort based on data from four nationwide health data registers, created with the aim of investigating how the use of selected medications influences cancer risk and other outcomes. PARTICIPANTS: The cohor...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Shao-Hua, Santoni, Giola, Mattsson, Fredrik, Ness-Jensen, Eivind, Lagergren, Jesper
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352833/
https://www.ncbi.nlm.nih.gov/pubmed/30696673
http://dx.doi.org/10.1136/bmjopen-2018-023155
_version_ 1783390924260245504
author Xie, Shao-Hua
Santoni, Giola
Mattsson, Fredrik
Ness-Jensen, Eivind
Lagergren, Jesper
author_facet Xie, Shao-Hua
Santoni, Giola
Mattsson, Fredrik
Ness-Jensen, Eivind
Lagergren, Jesper
author_sort Xie, Shao-Hua
collection PubMed
description PURPOSE: The Swedish Prescribed Drugs and Health Cohort (SPREDH) is a Swedish population-based cohort based on data from four nationwide health data registers, created with the aim of investigating how the use of selected medications influences cancer risk and other outcomes. PARTICIPANTS: The cohort includes 8 421 115 users of selected common medications who have been followed-up for a total of 82 281 720 person-years from 1 July 2005 to 31 December 2015. FINDING TO DATE: The data in SPREDH were prospectively collected from the following national health data registers in Sweden: Prescribed Drug Register, Patient Register, Cancer Register and Causes of Death Register. Data on basic patient characteristics, use of the selected common medications, healthcare utilisation, diagnoses (including detailed information on cancers), and dates and causes of death are available for all cohort participants. The cohort currently includes 801 766 incident cancer cases. FUTURE PLANS: The data in SPREDH can be used for various types of epidemiological research, particularly for examining how the use of the selected medications influences disease risk and other outcomes. We are initially planning cohort studies and nested case-control studies on selected medications in relation to the risk and prognosis of oesophageal and gastric cancers.
format Online
Article
Text
id pubmed-6352833
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-63528332019-02-21 Cohort profile: the Swedish Prescribed Drugs and Health Cohort (SPREDH) Xie, Shao-Hua Santoni, Giola Mattsson, Fredrik Ness-Jensen, Eivind Lagergren, Jesper BMJ Open Epidemiology PURPOSE: The Swedish Prescribed Drugs and Health Cohort (SPREDH) is a Swedish population-based cohort based on data from four nationwide health data registers, created with the aim of investigating how the use of selected medications influences cancer risk and other outcomes. PARTICIPANTS: The cohort includes 8 421 115 users of selected common medications who have been followed-up for a total of 82 281 720 person-years from 1 July 2005 to 31 December 2015. FINDING TO DATE: The data in SPREDH were prospectively collected from the following national health data registers in Sweden: Prescribed Drug Register, Patient Register, Cancer Register and Causes of Death Register. Data on basic patient characteristics, use of the selected common medications, healthcare utilisation, diagnoses (including detailed information on cancers), and dates and causes of death are available for all cohort participants. The cohort currently includes 801 766 incident cancer cases. FUTURE PLANS: The data in SPREDH can be used for various types of epidemiological research, particularly for examining how the use of the selected medications influences disease risk and other outcomes. We are initially planning cohort studies and nested case-control studies on selected medications in relation to the risk and prognosis of oesophageal and gastric cancers. BMJ Publishing Group 2019-01-28 /pmc/articles/PMC6352833/ /pubmed/30696673 http://dx.doi.org/10.1136/bmjopen-2018-023155 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Epidemiology
Xie, Shao-Hua
Santoni, Giola
Mattsson, Fredrik
Ness-Jensen, Eivind
Lagergren, Jesper
Cohort profile: the Swedish Prescribed Drugs and Health Cohort (SPREDH)
title Cohort profile: the Swedish Prescribed Drugs and Health Cohort (SPREDH)
title_full Cohort profile: the Swedish Prescribed Drugs and Health Cohort (SPREDH)
title_fullStr Cohort profile: the Swedish Prescribed Drugs and Health Cohort (SPREDH)
title_full_unstemmed Cohort profile: the Swedish Prescribed Drugs and Health Cohort (SPREDH)
title_short Cohort profile: the Swedish Prescribed Drugs and Health Cohort (SPREDH)
title_sort cohort profile: the swedish prescribed drugs and health cohort (spredh)
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352833/
https://www.ncbi.nlm.nih.gov/pubmed/30696673
http://dx.doi.org/10.1136/bmjopen-2018-023155
work_keys_str_mv AT xieshaohua cohortprofiletheswedishprescribeddrugsandhealthcohortspredh
AT santonigiola cohortprofiletheswedishprescribeddrugsandhealthcohortspredh
AT mattssonfredrik cohortprofiletheswedishprescribeddrugsandhealthcohortspredh
AT nessjenseneivind cohortprofiletheswedishprescribeddrugsandhealthcohortspredh
AT lagergrenjesper cohortprofiletheswedishprescribeddrugsandhealthcohortspredh